Allena Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALNA) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.02▼$0.1652-Week Range N/AVolumeN/AAverage Volume15.69 million shsMarket Capitalization$37,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesInsider TradesSocial MediaStock AnalysisCompetitorsHeadlinesInsider TradesSocial Media About Allena Pharmaceuticals Stock (NASDAQ:ALNA)Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Read More ALNA Stock News HeadlinesNovember 5, 2023 | morningstar.comAllena Pharmaceuticals Inc ALNAQ Stock QuoteAugust 28, 2023 | investing.comAllena Pharmaceuticals Inc (ALNAQ)December 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.May 6, 2023 | bizjournals.comSan Francisco Pharmaceuticals NewsSeptember 29, 2022 | reuters.comALNA.OSeptember 6, 2022 | wsj.comFirm Retention Summary: Allena Pharmaceuticals Inc.September 6, 2022 | finance.yahoo.comAllena Pharmaceuticals Shares Fall After Filing For BankruptcyAugust 11, 2022 | finance.yahoo.comAllena Pharma Needs To Raise Capital To Continue As A Going ConcernDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.August 11, 2022 | marketwatch.comAllena Pharmaceuticals Warns of Imminent Funding Need >ALNAJuly 19, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney DiseaseJuly 12, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock SplitJuly 12, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock SplitJuly 5, 2022 | apnews.comAllena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock SplitJuly 5, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock SplitJuly 1, 2022 | uk.investing.comWhy Shares Of Allena Pharmaceuticals Are Skyrocketing TodayJune 29, 2022 | investorplace.comALNA Stock Alert: What to Know as Allena Pharmaceuticals Soars 200%May 16, 2022 | msn.comShort Volatility Alert: Allena PharmaceuticalsMay 12, 2022 | investorplace.comALNA Stock Alert: 5 Things to Know as Little-Known Allena Pharmaceuticals Soars 100%May 12, 2022 | seekingalpha.comNano cap stock Allena surges on heavy volumeMay 4, 2022 | seekingalpha.comAllena Pharmaceuticals $2.8M direct offeringMay 4, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces $2.8 Million Registered Direct OfferingMarch 22, 2022 | seekingalpha.comAllena downgraded to Neutral at B. Riley citing the end to lead clinical programMarch 21, 2022 | finance.yahoo.comWhy Are Allena Pharma Shares Plunging TodayMarch 21, 2022 | seekingalpha.comAllena extends losses on plans to end trial for lead asset and financial concernsMarch 1, 2022 | finance.yahoo.comAllena Pharmaceuticals, Inc. (ALNA)January 29, 2022 | fool.comAllena Pharmaceuticals, Inc.(ALNA)See More Headlines Receive ALNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2022Today12/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological Products, Except Diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALNA CUSIPN/A CIK1624658 Webwww.allenapharma.com Phone(617) 467-4577Fax617-916-1871Employees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-287.46% Return on Assets-146.58% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / BookN/AMiscellaneous Outstanding Shares122,083,000Free Float117,566,000Market Cap$37,000.00 OptionableNot Optionable Beta1.13 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Alexey L. Margolin Ph.D. (Age 69)Co-Founder & Chairman Comp: $70kDr. Louis Brenner M.B.A. (Age 52)M.D., Pres, CEO & Director Comp: $576.86kDr. Richard D. Katz (Age 58)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $400.67kMr. Robert Gallotto (Age 57)Co-Founder & Strategic Adviser Mr. Geoffrey A. Swire (Age 49)Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer Mr. Hugh WightSr. VP of Technical OperationsDr. Alicja Januszewicz Ph.D.VP of People & CultureDr. David J. Clark (Age 57)Chief Medical Officer More ExecutivesKey CompetitorsGenocea BiosciencesNASDAQ:GNCAQG Medical InnovationsNASDAQ:GMVDFViewRayNASDAQ:VRAYQHTG Molecular DiagnosticsNASDAQ:HTGMQAllied Healthcare ProductsNASDAQ:AHPIView All Competitors ALNA Stock Analysis - Frequently Asked Questions How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) posted its quarterly earnings results on Thursday, March, 31st. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06. What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO? 1 employees have rated Allena Pharmaceuticals Chief Executive Officer Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among the company's employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN). When did Allena Pharmaceuticals IPO? (ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:ALNA) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.